Copy to clipboard 
Corin, a U.K. orthopedics company playing primarily in the joint replacement segment, accelerated its growth strategy by entering a binding agreement to purchase U.S.-based OMNI, makers of the OMNIBotics® robot-assisted total knee replacement system. The acquisition gives Corin a greater foothold in the U.S., the world’s largest orthopedic market where robotics is growing rapidly.
OMNIBotics combines a robotic cutting guide with what is billed as “the world’s first robotic tool to measure ligament function.” Combined with the Optimized Positioning System for hips, OMNIBotics gives Corin flagship technologies across multiple segments as they strive to create a connected digital ecosystem throughout a patient’s episode of care.
Corin is the latest orthopedic company to embrace the ecosystem model. The strategy aims to provide surgeons with end-to-end solutions that can result in better procedure flow with improved economic and clinical outcomes. To the company’s benefit, these ecosystems can nearly monopolize an operating room, making it very disruptive for surgeons to use another vendor. Additionally, many companies recognize the ability of robotics to drive improved sales mix by facilitating upselling.
ORTHOWORLD estimates that Corin is a top 15 player in knee and hip replacement, with total 2018 orthopedic revenue between US $130MM to $140MM. The addition of OMNIBotics gives Corin a distinct advantage over similarly-sized companies, arming them with a differentiated technology available to few companies outside of the top tier players.
Corin was already connected with OMNI through its 2018 acquisition of Australia-headquartered Global Orthopaedic Technology (GOT). GOT had exclusive rights to manufacture, market and distribute OMNI’s APEX™ Knee in Australia, South Africa and New Zealand. GOT also acquired rights to market OMNIBotics robotic-assisted total knee and computer-assisted total hip replacement technology in three countries.
Both Corin acquisitions were backed by Permira funds, which acquired Corin in 2018. The OMNI acquisition is expected to close in early March 2019. Financial terms were not disclosed.
Sources: Corin Group; ORTHOWORLD Inc.
Corin, a U.K. orthopedics company playing primarily in the joint replacement segment, accelerated its growth strategy by entering a binding agreement to purchase U.S.-based OMNI, makers of the OMNIBotics® robot-assisted total knee replacement system. The acquisition gives Corin a greater foothold in the U.S., the world’s largest orthopedic market...
Corin, a U.K. orthopedics company playing primarily in the joint replacement segment, accelerated its growth strategy by entering a binding agreement to purchase U.S.-based OMNI, makers of the OMNIBotics® robot-assisted total knee replacement system. The acquisition gives Corin a greater foothold in the U.S., the world’s largest orthopedic market where robotics is growing rapidly.
OMNIBotics combines a robotic cutting guide with what is billed as “the world’s first robotic tool to measure ligament function.” Combined with the Optimized Positioning System for hips, OMNIBotics gives Corin flagship technologies across multiple segments as they strive to create a connected digital ecosystem throughout a patient’s episode of care.
Corin is the latest orthopedic company to embrace the ecosystem model. The strategy aims to provide surgeons with end-to-end solutions that can result in better procedure flow with improved economic and clinical outcomes. To the company’s benefit, these ecosystems can nearly monopolize an operating room, making it very disruptive for surgeons to use another vendor. Additionally, many companies recognize the ability of robotics to drive improved sales mix by facilitating upselling.
ORTHOWORLD estimates that Corin is a top 15 player in knee and hip replacement, with total 2018 orthopedic revenue between US $130MM to $140MM. The addition of OMNIBotics gives Corin a distinct advantage over similarly-sized companies, arming them with a differentiated technology available to few companies outside of the top tier players.
Corin was already connected with OMNI through its 2018 acquisition of Australia-headquartered Global Orthopaedic Technology (GOT). GOT had exclusive rights to manufacture, market and distribute OMNI’s APEX™ Knee in Australia, South Africa and New Zealand. GOT also acquired rights to market OMNIBotics robotic-assisted total knee and computer-assisted total hip replacement technology in three countries.
Both Corin acquisitions were backed by Permira funds, which acquired Corin in 2018. The OMNI acquisition is expected to close in early March 2019. Financial terms were not disclosed.
Sources: Corin Group; ORTHOWORLD Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
